AMN Healthcare Services, Inc.
NYSE:AMNMedical - Care Facilities
-$1.29 today
- Market cap
- $1.45B
- Beta
- 0.44
- P/E (TTM)
- -37.3
- EPS (TTM)
- -$0.83
Volume 0.55M
Average 1.02M
AMN Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
AMN Healthcare Services, Inc.NYSE: AMN
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development remains negative
Q1 FY2026 research & development was $0, compared with $0 a year earlier. Trailing-twelve-month research & development was $0.
Context
- Research & development amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly research & development holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Research & Development vs competitors
How AMN compares with its peers on the latest reported figures
- AMN's LTM Mar 2026 research & development of $0 is the 8th highest of the 11 companies compared; the peer median is $44.21M.
- Research & development amounts to 0.0% of revenue for AMN, versus a peer median of 11.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Dec 2025 | $223.39M | +26.2% | +32.9% | — | |
| LTM Mar 2026 | $222.77M | -37.9% | -38.6% | 157.6% | |
| LTM Mar 2026 | $110.07M | -12.0% | +22.1% | — | |
| LTM Mar 2026 | $106.4M | -7.7% | +7.7% | 12.8% | |
| LTM Mar 2026 | $52.54M | +7.4% | +4.8% | 16.9% | |
| LTM Mar 2026 | $35.88M | -3.0% | -25.6% | 34.9% | |
| LTM Jun 2026 | $21.15M | +13.2% | +8.3% | 10.1% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding AMN) | $44.21M | -3.0% | +7.7% | 11.5% | |
Competitors are the stored peer set for AMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 3.98B | 5.24B | 3.79B | 2.98B | 2.73B |
| Cost of Revenue | 2.67B | 3.53B | 2.54B | 2.06B | 1.96B |
| Gross Profit | 1.31B | 1.72B | 1.25B | 919.38M | 774.06M |
| Gross Margin | 32.9% | 32.7% | 33.0% | 30.8% | 28.3% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 730.45M | 936.58M | 756.24M | 632.49M | 593.02M |
| Operating Expenses | 831.6M | 1.07B | 911.15M | 1.02B | 740.89M |
| Depreciation & Amortization | 103.7M | 137.11M | 160.93M | 173.78M | 156.6M |
| EBITDA | 581.7M | 784.21M | 499.36M | 71.11M | 101.13M |
| EBITDA Margin | 14.6% | 15.0% | 13.2% | 2.4% | 3.7% |
| Operating Income | 478M | 647.1M | 338.43M | (102.67M) | 33.17M |
| Operating Margin | 12.0% | 12.3% | 8.9% | -3.4% | 1.2% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 34.08M | 40.4M | 54.14M | 69.9M | 45.59M |
| Other Income / Expenses | (34.08M) | (40.4M) | (54.14M) | (69.9M) | (134.23M) |
| Income Before Tax | 443.92M | 606.7M | 284.29M | (172.57M) | (101.06M) |
| Pre-Tax Margin | 11.1% | 11.6% | 7.5% | -5.8% | -3.7% |
| Income Tax Expense | 116.53M | 162.65M | 73.61M | (25.6M) | (5.36M) |
| Net Income | 327.39M | 444.05M | 210.68M | (146.98M) | (95.7M) |
| Net Margin | 8.2% | 8.5% | 5.6% | -4.9% | -3.5% |
| EPS (Basic) | 6.87 | 9.96 | 5.38 | (3.85) | (2.48) |
| EPS (Diluted) | 6.81 | 9.90 | 5.36 | (3.85) | (2.48) |
| Weighted Avg Shares | 47.69M | 44.59M | 39.17M | 38.19M | 38.52M |
| Weighted Avg Shares (Diluted) | 48.05M | 44.87M | 39.34M | 38.19M | 38.52M |
AMN Healthcare Services, Inc.
NYSE:AMN
Intrinsic Alpha fair value
Locked
Current Price
$37.60
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.